---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-105053"
form_type: "8-K"
ticker: "CTMX"
cik: "0001501989"
company_name: "CytomX Therapeutics, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:28:14.768455+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CytomX Q2 2025 cash $158.1M; positive CX-2051 Phase 1 data; $100M offering closed

## Summary
- Revenue $18.7M in Q2 2025 vs $25.1M in Q2 2024; operating expenses fell to $19.9M from $33.6M.
- Cash, equivalents and investments $158.1M at June 30, 2025, up from $79.9M on March 31, 2025; cash runway to Q2 2027.
- Positive interim data from CX-2051 Phase 1 in advanced colorectal cancer; dose expansions initiated at 7.2, 8.6, 10 mg/kg Q3W.
- CX-2051 Phase 1 data update on ~70 patients by Q1 2026; Phase 2 study in late-line CRC expected in 1H 2026.
- Completed $100M underwritten offering, net proceeds $93.4M; CX-801 plus KEYTRUDA dose escalation started for advanced melanoma.

## SEC filing metadata
- accession: 0000950170-25-105053
- form_type: 8-K
- ticker: CTMX
- cik: 0001501989
- company_name: CytomX Therapeutics, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501989/000095017025105053/0000950170-25-105053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501989/000095017025105053/ctmx-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-105053
- JSON: https://secwatch.observer/filing/0000950170-25-105053.json
- Plain text: https://secwatch.observer/filing/0000950170-25-105053.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.